# Stabilities of Ac3+ Complexes Relevant as Radiopharmaceuticals

**Authors:** Antía Freire-García, Raúl Alvarado, María Costa-DeDios, David Esteban-Gómez, Carlos Platas-Iglesias

PMC · DOI: 10.1021/acs.inorgchem.5c05846 · 2026-02-24

## TL;DR

This study uses computer modeling to compare the stability of Ac3+ and La3+ complexes, aiming to improve the design of radiopharmaceuticals for cancer therapy.

## Contribution

The paper introduces a DFT-based methodology to estimate Ac3+ complex stabilities using La3+ data, enabling better chelator design for radiopharmaceuticals.

## Key findings

- Ac3+ coordination bond distances are longer than La3+, suggesting a larger ionic radius of 1.275 ± 0.020 Å for Ac3+.
- Ac3+ complexes are generally less thermodynamically stable than La3+ ones, except for MACROPA2– and OCTAPA4–.
- The proposed methodology helps identify suitable chelators for Ac3+ in targeted alpha therapy.

## Abstract

We present a detailed density functional theory (DFT)
investigation
of the structural features and thermodynamic stabilities of La3+ and Ac3+ complexes relevant to develop radiopharmaceutical
agents. A total of 16 chelators were considered, covering the acyclic
and macrocyclic families functionalized with different numbers and
types of donor atoms. The bond distances of the Ac3+ coordination
environment are systematically longer than those obtained for the
La3+ analogues, which allowed us to estimate an ionic radius
for Ac3+ in coordination number 9 of 1.275 ± 0.020
Å (1.216 and 1.206 Å were proposed for La3+).
Energy decomposition analysis (EDA) provided hints into the nature
of the metal–ligand interactions and their relative weight
in La3+ and Ac3+ complexes. A thermodynamic
DFT study allowed us to estimate the stability constants of the Ac3+ complexes from those of the La3+ ones, as for
the latter experimental values are available in the literature. These
studies evidenced that Ac3+ tends to form complexes with
lower thermodynamic stability in comparison with La3+,
with the exception of one of the leading chelators for Ac3+, MACROPA2–, and the unexpected case of OCTAPA4–. Overall, the methodology reported here will allow
identifying chelators well suited for Ac3+ coordination,
thereby aiding the design of radiopharmaceuticals based on [225Ac]­Ac3+ for targeted α therapy (TAT).

## Linked entities

- **Chemicals:** La3+ (PubChem CID 104897)

## Full-text entities

- **Genes:** TAT (tyrosine aminotransferase) [NCBI Gene 6898]
- **Diseases:** cytotoxic (MESH:D064420), tumor (MESH:D009369)
- **Chemicals:** pyridine (MESH:C023666), Def (MESH:C006863), DOTAM (-), amine (MESH:D000588), 228Ac (MESH:C000615156), lanthanide (MESH:D028581), 225Ac (MESH:C000615155), DOTA (MESH:C071349), 232Th (MESH:C000615164), O (MESH:D010100), actinide (MESH:D008671), metal (MESH:D008670), 227Ac (MESH:C000617035), Gd3+ (MESH:C026226), C (MESH:D002244), Ac (MESH:D000186), N2 (MESH:D009584), NPY (MESH:C065586), 235U (MESH:C000615176), H2O (MESH:D014867), La (MESH:D007811), amides (MESH:D000577), ethanol (MESH:D000431), bispidine (MESH:C495809), picolinate (MESH:C030614)
- **Mutations:** DeltaG 298

## Figures

12 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12977054/full.md

---
Source: https://tomesphere.com/paper/PMC12977054